ArticleNPJ precision oncology2026
Distinct metabolic profiles in lung adenocarcinomas presenting as solid or ground-glass opacities.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Metabolomic profiling provides real-time insights into tissue physiology and upstream molecular events. Despite its potential in cancer research, large-scale integrative studies in lung adenocarcinoma (LUAD) remain scarce. We analyzed 262 tissue samples from 165 LUAD patients using metabolomic, transcriptomic, and 16S rRNA sequencing, integrating data through a "gene-enzyme-reaction-metabolite" network. Distinct components of mixed ground-glass opacities (mGGOs) and lesions from multiple primary lung cancers (MPLC) were also evaluated separately. Our results revealed extensive metabolic reprogramming in LUAD, predominantly affecting glycerophospholipid metabolism. Pure ground-glass opacities (GGOs) and solid nodules (SNs) exhibited markedly distinct metabolic profiles, with linoleic acid metabolism as a key differentiator. In contrast, components within mGGOs were metabolically similar, resembling pure GGOs. Cellular and organoid models demonstrated that phospholipase A2 (PLA2) inhibition or phosphatidylcholine (32:0) treatment significantly attenuated invasion and proliferation of LUAD cells. These findings provide a metabolic basis for subtype-specific LUAD biology and potential therapeutic strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.